Panelists discuss how atopic dermatitis, a chronic inflammatory skin condition characterized by intense itching and recurring ...
Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the enrollment of the first patient in a ...
4d
MedPage Today on MSNRapid Improvement in Atopic Dermatitis With Dual JAK/TYK2 InhibitorORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...
Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...
Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...
Joya Griffin, DVM, DACVD, discusses the concept of ‘food as medicine’ and how prescription diets can help restore the skin’s ...
6d
Amazon S3 on MSNUnderstanding Atopic DermatitisDutz, Skin Centre, Vancouver, BC, talks about what Atopic Dermatitis is, it's symptoms and how it is diagnosed.
Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low dise ...
7d
Clinical Trials Arena on MSNAmgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpointsAll the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.
Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...
Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according ...
Lebrikizumab is comparable or superior to many advanced systemic monotherapies for the short-term treatment of atopic dermatitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results